Annexon/ANNX

$4.96

5.53%
-
1D1W1MYTD1YMAX

About Annexon

Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.

Ticker

ANNX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Douglas Love

Employees

70

Headquarters

Brisbane, United States

Annexon Metrics

BasicAdvanced
$434M
Market cap
-
P/E ratio
-$1.46
EPS
1.29
Beta
-
Dividend rate
$434M
1.28874
$8.40
$1.57
1.9M
20.615
-42.15%
-50.6%
-44.99%
1.621
1.655
40.88%

What the Analysts think about Annexon

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 5 analysts.
206.45% upside
High $30.00
Low $10.00
$4.96
Current price
$15.20
Average price target

Annexon Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$25M
-9.71%
Profit margin
0%
NaN%

Annexon Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 38.47%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.47
-$0.43
-$0.36
-$0.21
-
Expected
-$0.54
-$0.50
-$0.44
-$0.34
-$0.23
Surprise
-13.56%
-14.47%
-17.34%
-38.47%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Annexon stock?

Annexon (ANNX) has a market cap of $434M as of May 26, 2024.

What is the P/E ratio for Annexon stock?

The price to earnings (P/E) ratio for Annexon (ANNX) stock is 0 as of May 26, 2024.

Does Annexon stock pay dividends?

No, Annexon (ANNX) stock does not pay dividends to its shareholders as of May 26, 2024.

When is the next Annexon dividend payment date?

Annexon (ANNX) stock does not pay dividends to its shareholders.

What is the beta indicator for Annexon?

Annexon (ANNX) has a beta rating of 1.29. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Annexon stock price target?

The target price for Annexon (ANNX) stock is $15.2, which is 206.45% above the current price of $4.96. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Annexon stock

Buy or sell Annexon stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing